pp-105 Gel
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Androgenetic alopecia (pattern hair loss) in adult patients seeking hair regrowth treatment
Clinical stage: Phase 3 global clinical development
Modality: Small molecule topical agent
Mechanism / Target: Targets hair follicle biology to promote hair regrowth through modulation of local signaling pathways involved in follicle cycling
Route / form: Topical application (solution/gel)
Differentiation: Designed as a novel topical hair regrowth therapy with potential for improved efficacy and tolerability compared with existing treatments for androgenetic alopecia
Manufacturer #11806
Clinical-stage biopharma focused on autoimmune and inflammatory diseases. Pipeline emphasizes selective oral small molecules with improved safety profiles. Active in global development and strategic partnerships.